Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas

Slides:

Advertisements

Similar presentations

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Advertisements

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer Babatunde A. Yerokun, MD, Chi-Fu.

Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma Yingjie.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis Nathan M. Mollberg, DO,

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus Yang Zhao, MD, ZhiJun Dai,

Ratio of Metastatic Lymph Nodes to Total Number of Nodes Resected is Prognostic for Survival in Esophageal Carcinoma Clive J. Kelty, MB, ChB, PhD, FRCSEd,

Now or Later: Evaluating the Importance of Chemotherapy Timing in Resectable Stage III (N2) Lung Cancer in the National Cancer Database Daniel J. Boffa,

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Impact of Solid Minor Histologic Subtype in Postsurgical Prognosis of Stage I Lung Adenocarcinoma Tianxiang Chen, MD, PhD, Jizhuang Luo, MD, Haiyong.

Surgical quality of wedge resection affects overall survival in patients with early stage non–small cell lung cancer Gaurav S. Ajmani, MHS, Chi-Hsiung.

Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non–Small Cell Lung Cancer Christina K. Speirs, MD, PhD, Todd.

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases Åslaug Helland, MD, PhD, Steinar Solberg,

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Yih-Leong Chang, MD, Chen-Tu Wu, MD, Yung-Chie Lee, MD, PhD

Increasing Age and Carcinoma Not Otherwise Specified: A 20-Year Population Study of 40,118 Lung Cancer Patients Camilla Maria T. Sagerup, MD, Milada.

Matthew J. Boyer, MD, PhD, Christina D. Williams, PhD, MPH, David H

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non–Small Cell Lung Cancer Junghoon Shin, MD, Bhumsuk Keam, MD, PhD, Miso.

Castigliano M. Bhamidipati, DO, MS, George J

Ze-Rui Zhao, MD, Calvin S.H. Ng, MD, FRCS

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer Boris Sepesi, MD, Kathryn A. Gold, MD,

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Conditional Cancer-Specific Versus Cardiovascular-Specific Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer Shawn S. Groth, MD, MS, Natasha.

A. Marc Gillinov, MD, Eugene H. Blackstone, MD, Edward R

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis Elizabeth A. David, MD, Megan E.

Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer Jianlin Xu, MD, Haitang Yang, MD, Xiaolong Fu, MD, Bo Jin,

Number of Lymph Nodes Associated With Maximal Reduction of Long-Term Mortality Risk in Pathologic Node-Negative Non–Small Cell Lung Cancer Raymond U.

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Andrew P. Dhanasopon, MD, Michelle C. Salazar, MD, Jessica R

Tumor Spread through Air Spaces Affects the Recurrence and Overall Survival in Patients with Lung Adenocarcinoma >2 to 3 cm Chenyang Dai, MD, Huikang.

Thoracoscopic Lobectomy Produces Long-Term Survival Similar to That with Open Lobectomy in Cases of Non–Small Cell Lung Carcinoma: A Propensity-Matched.

Onkar V. Khullar, MD, Yuan Liu, PhD, Theresa Gillespie, PhD, Kristin A

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Loss of p16INK4A Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas Scott W. Aesif, MD,

Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma Yingjie.

The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients

Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Jiro Okami, MD, PhD, Yuri Ito, PhD, Masahiko.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Posttransplant Outcomes Among Septuagenarians Bridged to Transplantation With Continuous-Flow Left Ventricular Assist Devices Shinichi Fukuhara, MD,

Does Lymph Node Metastasis Have a Negative Prognostic Impact in Patients with NSCLC and M1a Disease? Chenyang Dai, MD, Yijiu Ren, MD, Dong Xie, MD, PhD,

Refining the Nodal Staging for Esophageal Squamous Cell Carcinoma Based on Lymph Node Stations Jun Peng, MD, Wen-Ping Wang, MD, Ting Dong, MD, Jie Cai,

Should Large Cell Neuroendocrine Lung Carcinoma be Classified and Treated as a Small Cell Lung Cancer or with Other Large Cell Carcinomas? John M. Varlotto,

It’s All in the “Swerve of the Curve”

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Extent of lymphadenectomy is associated with oncological efficacy of sublobar resection for lung cancer ≤2 cm Brendon M. Stiles, MD, Jialin Mao, MD,

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

Influence of Ground Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non–Small Cell Lung Cancer

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung.

Figure 2. Forest plot of multivariable Cox proportional hazard regression illustrating the impact of chemoradiation ... Figure 2. Forest plot of multivariable.

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

Volume 20, Issue 8, Pages (August 2019)

Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database Sukhmani.

Presentation transcript:

Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas Ze-Rui Zhao, MD, Dong-Rong Situ, MD, Rainbow W.H. Lau, MbChB., Tony S.K. Mok, MD, FRCPC, George G. Chen, PhD, Malcolm J. Underwood, MD, Calvin S.H. Ng, MD Journal of Thoracic Oncology Volume 12, Issue 5, Pages 890-896 (May 2017) DOI: 10.1016/j.jtho.2017.01.012 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Flow diagram of the study. Journal of Thoracic Oncology 2017 12, 890-896DOI: (10.1016/j.jtho.2017.01.012) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 (A) Standardized differences of variables between patients who received lobectomy and segmentectomy. Red crosses symbolize differences before propensity matching and blue circles symbolize differences after propensity matching. Propensity score matching effectively reduced heterogeneity among variables between the two groups in comparison. (B) Mirror histogram of propensity scores for patients who received segmentectomy (below the horizontal line at zero) and lobectomy (above the horizontal line at zero). Matched patients are a subset of the original patient population and their volumes are highlighted in color. Matched groups have similar propensity score distributions. Journal of Thoracic Oncology 2017 12, 890-896DOI: (10.1016/j.jtho.2017.01.012) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Survival curves adjusted for age, sex, histological subtype, and lymph node quantity compare treatment with segmentectomy versus with lobectomy in patients with pathological stage IA adenocarcinoma (>10 and ≤20 mm) after propensity score matching for overall (A) and lung cancer–specific (B) survival. Shaded area represents the confidence limits for each group. Journal of Thoracic Oncology 2017 12, 890-896DOI: (10.1016/j.jtho.2017.01.012) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 4 Multivariable Cox proportional hazards model adjusted for age, sex, histological type, and lymph node quantity for overall (A) and lung cancer–specific (B) survival by subgroup analysis in the matched population. Dashed line indicates the prespecified noninferiority margin of 1.25. Blue shaded band represents the 95% confidence interval (CI) of the hazard ratio (HR) for the overall matched population. BAC, bronchioloalveolar carcinoma; Seg, segmentectomy; Lob, lobectomy. Journal of Thoracic Oncology 2017 12, 890-896DOI: (10.1016/j.jtho.2017.01.012) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplemental Figure 1 Unadjusted survival curves compare treatment with segmentectomy versus lobectomy in patients with pathological stage IA adenocarcinoma (>10 and ≤20 mm) for overall and lung cancer-specific survival in the entire cohort (A, B), and in the matched population (C, D). The shaded area represents the confidence limits for each group. Journal of Thoracic Oncology 2017 12, 890-896DOI: (10.1016/j.jtho.2017.01.012) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplemental Figure 2 Unadjusted Survival curves compare different number of lymph nodes evaluated in patients with pathological stage IA adenocarcinoma (>10 and ≤20 mm) in the entire cohort for (A) overall and (B) lung cancer-specific survival. The shaded area represents the confidence limits for each group. Journal of Thoracic Oncology 2017 12, 890-896DOI: (10.1016/j.jtho.2017.01.012) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions